$103.46
-0.0139-0.01%
At close: Sep 11, 5:00 PM EST
Tools
Free Benzinga Pro Trial
Calendars
Trade Ideas
Short Interest
Calculators
Compare Best Stocks
Virtus Biotech ETF (BBP) Stock Price, Quote, News & History | Benzinga
Edge Rankings
Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
Sector
Healthcare
Region
US
AUM
118.07M
Fund Score
Loading...
Key Statistics
Open
$104.48
High
$104.51
52 Wk High
$110.05
AUM
118.07M
Dividend
-
Ex-Div Date
-
Volume
8.26K
Market Cap
$15.40B
Mgmt Fee
0.34%
P/E Ratio
11.46
Prev. Close
$103.47
Low
$103.45
52 Wk Low
$68.05
Shares Out
350.00K
Yield
-
Div. Freq
-
Avg. Volume Daily
9.21K
Beta
0.57
Avg. Expense Ratio
0.34%
P/B Ratio
4.60
Recent Virtus Biotech ETF News
FAQ
Q
How do I buy Virtus Biotech ETF (BBP) stock?
A
You can purchase shares of Virtus Biotech ETF (ARCA:BBP) through any online brokerage.
Q
Who are Virtus Biotech ETF (BBP) competitors?
A
There are no as such competitors for Virtus Biotech ETF.
Q
What is the forecast, or price target, for Virtus Biotech ETF (BBP) stock?
A
There is no analysis for Virtus Biotech ETF to provide a consensus price target.
Q
What is the current price for Virtus Biotech ETF (BBP)?
A
The stock price for Virtus Biotech ETF (ARCA: BBP) is $ last updated .
Q
Does Virtus Biotech ETF (BBP) pay a dividend?
A
There are no upcoming dividends for Virtus Biotech ETF.
Q
When is Virtus Biotech ETF (ARCA:BBP) reporting earnings?
A
Virtus Biotech ETF does not have any upcoming earnings scheduled.
Q
Is Virtus Biotech ETF (BBP) going to split?
A
There is no upcoming split for Virtus Biotech ETF.
Key Statistics
Open
$104.48
High
$104.51
52 Wk High
$110.05
AUM
118.07M
Dividend
-
Ex-Div Date
-
Volume
8.26K
Market Cap
$15.40B
Mgmt Fee
0.34%
P/E Ratio
11.46
Prev. Close
$103.47
Low
$103.45
52 Wk Low
$68.05
Shares Out
350.00K
Yield
-
Div. Freq
-
Avg. Volume Daily
9.21K
Beta
0.57
Avg. Expense Ratio
0.34%
P/B Ratio
4.60
About
Sector
N/A
Industry
N/A
ETF Details
| Sector | Healthcare |
| Category | Mid Performer-Mid Growth |
| Investment Style | Mid Cap Growth |
| Fund Inception | Dec 16, 2014 |
| Managers | Seth Kadushin Paul Yook Andrew McDonald Matthew B. Brown |
| Definition | Most of the stocks in this equity fund have average financial performance and average growth potential |
Investment Policy
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration (FDA) for marketing.
Top ETF Holdings
| Symbol | Name | Share % |
|---|---|---|
| KNSA | Kiniksa Pharmaceutical... | 2.00% |
| CRNX | Crinetics Pharmaceutic... | 3.24% |
| VSTM | Verastem Inc | 1.91% |
| NUVB | Nuvation Bio Inc | 1.72% |
| OMER | Omeros Corp | 1.93% |
| GERN | Geron Corp | 1.89% |
| PTGX | Protagonist Therapeuti... | 1.67% |
| PGEN | Precigen Inc | 2.06% |
| ACAD | Acadia Pharmaceuticals... | 1.82% |
| REGN | Regeneron Pharmaceutic... | 1.67% |
Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API
Market data provided by Benzinga APIs
Market Resources
Trading Tools & Education
- Benzinga Pro Trading Platform
- Options Trading Strategies and News
- Stock Market Trading Ideas and Analysis
- Technical Analysis Charts and Indicators
- Fundamental Analysis and Valuation
- Day Trading Guides and Strategies
- Live Investor Events
- Pre-market Stock Analysis and News
- Cryptocurrency Market Analysis and News
Ring the Bell
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.
© 2026 Benzinga | All Rights Reserved